References:
1. McCutcheon RA, Weber LAE, Nour MM, et al. Psychosis as a disorder of muscarinic signalling: psychopathology and pharmacology. Lancet Psychiatry 2024; 11: 554–565.
2. Wang Y, Yang Y, Xu W, et al. Heterogeneous brain abnormalities in schizophrenia converge on a common network associated with symptom remission. Schizophr Bull 2024; 50: 545–556.
3. Luo Y, Dong D, Huang H, et al. Associating multimodal neuroimaging abnormalities with the transcriptome and neurotransmitter signatures in schizophrenia. Schizophr Bull 2023; 49: 1554–1567.
4. Saint-Georges Z, MacDonald J, Al-Khalili R, et al. Cholinergic system in schizophrenia: a systematic review and meta-analysis. Mol Psychiatry 2025; 30: 3301–3315.
5. Paul SM, Yohn SE. Targeting muscarinic receptors for treating schizophrenia. Neurotherapeutics 2026; 23: e00839.
Muscarinic neurotransmission in schizophrenia
